Mikhail Blagosklonny is Spreading Awareness of the Practice of Oncology

An established professor of oncology at the Roswell Park Cancer Institute, Mikhail Blagosklonny’s studies lie primarily in the realm of cancer and aging. He earned an MD in internal medicine at the Medical University of St. Petersburg, where he also earned a Ph.D. in Experimental Medicine and Cardiology. In the New York Medical College, located in Valhalla, New York, Blagosklonny was appointed the associate professor of medicine. This opened doors for him to transfer from the college to serve as the senior scientist at the Ordway Research Institute and eventually he joined the Roswell Park Cancer Institute in the position of Professor of Oncology, as recent as 2009.

His experience is apparent in the handful of roles he’s worked in and has gained invaluable knowledge along his journey, which he now brings to the table in order to enrich the education of his students at the Ordway Research Institute. At the heart of his interests for research is Biogerontology, which is the study of the underlying details behind aging. The professor also teaches and actively researches in subjects including cancer, anti-aging drugs, and in methods that target cancer cells in order to prevent healthy cells from being affected. So, in essence, cancer prevention methods and medicines.

View: https://scholar.google.com/citations?user=REO9YogAAAAJ&hl=en

Aside from his role as Professor of Oncology, Mikhail Blagosklonny also holds a position as the editor-in-chief of Oncotarget and Cell Cycle and as such, serves also as the associate editor of cancer biology and therapy. Among his many positions as an oncology professional, he has also received the esteemed position on the editorial board for Cell Death and Differentiation. During his extensive studies, Mikhail has a strong belief in the drug Rapamycin, which is a popular drug used in treating cancer. He hypothesizes that it is a possible solution for use in life extension and has been deemed one of the more passionate oncologists in support of the drug Rapamycin. He has dedicated much of his time in researching the drug and its benefits in longevity treatment.

Mikhail Blagosklonny’s research into Rapamycin ranges from molecular biology studies to cellular to clinical investigations. It includes in large part tumor suppressors, ontogenesis, signal transduction, apoptosis, anticancer therapeutics, mitosis, cell cycle, and normal cells selective protection. As such, Mikhail is an avid writer on these subjects and writs about these topics, as well as other topics that interest him, such as aging hyperfunction theory, chemotherapeutic engineering, and cell cyclotherapy. Visit classroomvoices.org to read more about Mikhail.

Omar Boraie: Helping The Development Of Cancer Treatment Research

Omar Boraie is a man who has worked extremely hard for the betterment of society. His various philanthropic and professional endeavors have led to the incredible development of the city of New Brunswick, a place where the Boraie company first laid its roots. Continuing on his mission to help the community, Omar recently donated a total of $1.5 million towards the development and research of new treatments for combating cancer, reports patch.com.

Hailing from Egypt, Omar originally came to America to pursue a Ph. D in Chemistry. After completing his educational course, Omar decided to expand his family’s business into the city of New Brunswick and turn the then run downtown into a hub of residential excellence. Omar had a vision in mind for the development of the community of New Brunswick and implemented his goal in the most efficient way to make the city what it is today.

The pledge to donate $1.5 million was made as part of a ‘Chair Challenge’ started up by Rutgers University. The rules of the challenge were simple. A person can donate a certain amount of money towards the Institute, and also, an anonymous donor will match the pledged amount. In the end, the university will be receiving double the amount that was initially promised.

Omar’s donation was made with the aim of helping the universities genomic science department. The genomic science department of Rutgers University has been known to have made some of the most groundbreaking advances in the field of medical research. Most recently, the department has made revolutionary discoveries when it comes to genomic science which can extensively benefit patients in the treatment of cancer. With the new research in place, doctors who are treating patients with cancer now have the option to tailor the treatment for each patient, owing to the new technology to tackle the cancerous tumour from the genetic level. This research is proven to be extremely beneficial in the treatment of cancer and also for the development of cancer research.

This isn’t the first time that Omar has partaken on a journey to help the medical industry. In the past, he has repeatedly pledged for the development of research, in various medical fields. Omar has always aimed to make New Brunswick a city where healthcare is one of the top priorities. By pledging this amount to Rutgers University, Omar is paving the path for the development of medical institutions in New Brunswick and as well as the entire field of cancer research.